Exelixis, Inc.
EXELHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeExelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. At a $14.62B market cap, Exelixis, Inc. ranks as a large-cap company within healthcare. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Market Cap
$14.62B
Beta
0.42
P/E (TTM)
18.56
P/E (Fwd)
13.85
EPS (TTM)
$3.18
EPS (Fwd)
$4.26
ROE
44.4%
ROA
24.0%
Cash
$839.4M
Total Debt
$165.9M
Free CF
$739.7M
52W Change
54.1%
Annual Financials
Cash vs Debt
Where EXEL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, EXEL finished 19.99% above its 150-day moving average ($48.78) and 23.27% above its 200-day moving average ($47.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EXEL overbought or oversold?
At the September 3, 2026 close, EXEL's RSI(14) was 78.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $839.4M in cash and $165.9M in debt, EXEL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $739.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 44.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 24.0% further supports the picture of efficient asset utilization. Revenue has grown from $1.61B (2022) to $2.32B (2025), reflecting a 44% increase over the period.
With a beta below 0.7, Exelixis, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing EXEL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.